MedTrace Logo

13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.

NCT05025878 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2024-08-09

No results posted yet for this study

Summary

The objective of the study is to investigate the metabolism of cells in the ascites tumour microenvironment of ovarian cancer patients. This observational study involves intravenous infusion of \[U-13C\]glucose into patients during standard paracentesis.

Conditions

Interventions

DIETARY_SUPPLEMENT

[U-13C]Glucose

Patients are intravenously infused with 28g of \[U-13C\]glucose over a 5 hour period. Briefly, \[U-13C\]glucose will be provided by intravenous line containing 8g of \[U-13C\]glucose in 60 mL over 10 min. After 10 minutes, 4g of \[U-13C\]glucose will be administered over an hour. This process will continue until the patient's ascites is drained, or after 5 hours. We will monitor blood glucose levels during infusions using a continuous glucose monitor.

Sponsors & Collaborators

  • University of Texas Southwestern Medical Center

    collaborator OTHER

  • Van Andel Research Institute

    collaborator OTHER

  • University of Victoria

    collaborator OTHER

  • British Columbia Cancer Agency

    lead OTHER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-20
Primary Completion
2024-08-31
Completion
2024-08-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05025878 on ClinicalTrials.gov